GSA Capital Partners LLP Cuts Stock Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

GSA Capital Partners LLP reduced its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 57.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,202,906 shares of the biopharmaceutical company’s stock after selling 1,627,753 shares during the quarter. GSA Capital Partners LLP’s holdings in Lexicon Pharmaceuticals were worth $1,624,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of LXRX. Vanguard Personalized Indexing Management LLC increased its stake in Lexicon Pharmaceuticals by 77.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 28,594 shares during the period. Catalyst Funds Management Pty Ltd bought a new position in shares of Lexicon Pharmaceuticals in the second quarter worth approximately $51,000. R Squared Ltd purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter worth $28,000. Savant Capital LLC raised its holdings in Lexicon Pharmaceuticals by 33.2% during the 2nd quarter. Savant Capital LLC now owns 69,578 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 17,348 shares during the last quarter. Finally, Cerity Partners LLC boosted its position in Lexicon Pharmaceuticals by 21.1% during the 2nd quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 35,892 shares during the period. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Trading Up 0.8%

Shares of LXRX opened at $1.32 on Wednesday. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.28 and a 1-year high of $1.83. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average price is $1.28 and its 200-day moving average price is $1.30. The firm has a market capitalization of $479.78 million, a price-to-earnings ratio of -6.95 and a beta of 0.98.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $3.23.

Insiders Place Their Bets

In other news, Director Invus Global Management, Llc bought 1,538,462 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was purchased at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the transaction, the director owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 13.90% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.